Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Logmax Joint is a multi-ingredient supplement developed by Lloyd Healthcare (Syrus Division) for the management of orthopedic and musculoskeletal disorders. It contains a combination of calcium carbonate, *Cissus quadrangularis* extract, and Vitamin K2-7. Calcium carbonate serves as a primary calcium source for bone mineralization. *Cissus quadrangularis*, a medicinal plant, is traditionally used to promote bone healing and reduce inflammation. Vitamin K2-7 (menaquinone-7) plays a critical role in bone health by activating osteocalcin, which helps bind calcium to the bone matrix. The product is indicated for metabolic bone diseases, particularly in patients with chronic kidney failure not receiving dialysis, and for addressing calcium deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Logmax Joint.